Another clinical trial conducted by Adusumilli et al. yielded similarly encouraging results, with 8 out of 11 patients with mesothelioma responding to anti-mesothelin CAR-T cells and anti-PD-1 antibodies, including complete metabolic responses in two patients [211, 212]. Here, PDCD1 is linked to mesothelioma.